ZUO LI YAO YE(SZ:300181) Guohai Securities·2025-04-30 02:41Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company's core products are experiencing stable growth, with a high dividend payout ratio maintained above 80% for two consecutive years [4][6]. - In 2024, the company achieved a revenue of 2.578 billion yuan, a year-on-year increase of 32.71%, and a net profit attributable to shareholders of 508 million yuan, also up by 32.60% [4]. - For Q1 2025, the company reported a revenue of 824 million yuan, reflecting a year-on-year growth of 22.52%, and a net profit of 181 million yuan, up by 27.20% [4]. Summary by Sections Revenue and Profit Growth - The company’s core product, Wuling Mushroom Powder, is a new type of traditional Chinese medicine, contributing significantly to revenue. In 2024, the Wuling series generated 1.438 billion yuan, a growth of 17.14%, accounting for 55.79% of total revenue [6]. - The company expects revenue for 2025, 2026, and 2027 to be 3.263 billion, 4.115 billion, and 5.120 billion yuan respectively, with growth rates of 27%, 26%, and 24% [8]. Cost Management and Efficiency - The company has shown significant cost reduction and efficiency improvements, with a sales expense ratio of 32.53%, down by 7.5 percentage points year-on-year, and a management expense ratio of 4.28%, down by 0.7 percentage points [6]. Dividend Policy - The company plans to distribute a cash dividend of 415 million yuan for 2024, maintaining a dividend payout ratio exceeding 80% [6]. Earnings Forecast - The forecasted net profit for 2025, 2026, and 2027 is 662 million, 861 million, and 1.101 billion yuan respectively, with corresponding growth rates of 30% for 2025 and 2026, and 28% for 2027 [8].